基調講演・プレナリーセッション

3月6日（月）

8:00 am Chairperson's Remarks
Edward Abrahams, PhD, President, Personalized Medicine Coalition

8:05 am Sponsored Presentation (Opportunity Available)

8:15 am KEYNOTE PRESENTATION: Precision Medicine, What's So Difficult? The Interplay & Complexities of Pharmaceutical & Diagnostic Partnerships to Deliver the Promise of Precision Medicine
Sarah Hersey, MS, MBA, RAC, Vice President, Precision Medicine, Bristol Myers Squibb Co.
Numerous dynamic intricacies exist between pharmaceutical and diagnostic industries which require careful consideration when deploying precision medicine solutions. This, coupled with technological advances and an evolving regulatory landscape, results in significant complexity. From the push to try to incorporate precision medicine earlier in drug development, through commercialization, what are the potential opportunities as well as hurdles to overcome to enable more effective collaborations to deliver targeted therapies?

8:45 am PANEL DISCUSSION: Rx/Dx Collaborations: Strategies for Bringing Targeted Therapies to Market
Moderator: Edward Abrahams, PhD, President, Personalized Medicine Coalition
This session will explore challenges and strategies to discover and develop personalized medicines from the points of view of both the diagnostic and pharmaceutical industries.

Panelists:

Christopher Conn, PhD, Director, Diagnostics Strategy, Amgen

Marielena Mata, PhD, Senior Director and Diagnostic Lead, Oncology Program, Pfizer Inc.

David Fabrizio, Vice President, Translational Strategy, Foundation Medicine

Sarah Hersey, MS, MBA, RAC, Vice President, Precision Medicine, Bristol Myers Squibb Co.

3:40 pm Chairperson's Remarks
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing

3:45 pm FIRESIDE CHAT: Sequences, SynBio, and Sailing: Three Decades of Adventure with J. Craig Venter
Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing

J. Craig Venter, PhD, Founder, Chairman, and CEO, J. Craig Venter Institute
Since his riveting publication on expressed sequence tags in 1991, which galvanized a revolution in genomics, J. Craig Venter has been a dominant figure in the world of genomics and biotechnology. As the first human to have his personal genome completely sequenced, and as the co-founder of Synthetic Genomics and Human Longevity, he is routinely one step ahead of his peers. As we celebrate 30 years of TRI-CON, we're thrilled to host Dr. Venter who will discuss his life, his many accomplishments, and his vision for the future of precision medicine and the biotech industry.

4:15 pm PANEL DISCUSSION: 30 Years of Genomics Innovation and the Future of Precision Medicine
Moderator: Kevin Davies, PhD, Executive Editor, The CRISPR Journal; Author, Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Over the past three decades, genomic medicine has been transformed from a distant dream to a clinical reality. With patients suffering genetic diseases and cancer now cured thanks to advances in genomics, cell therapy, genome editing, and computing, the future is bright - but by no means assured. In this TRI-CON keynote panel, we discuss the scientific highlights of an extraordinary journey for practitioners of precision medicine and anticipate where the field is headed.

Panelists:

Euan Ashley, PhD, Professor, Genomics & Precision Health, Stanford School of Medicine

J. Craig Venter, PhD, Founder, Chairman, and CEO, J. Craig Venter Institute

Molly He, PhD, CEO & Co Founder, Element Biosciences

Alex Aravanis, MD, PhD, CTO, Senior Vice President, Head of Research and Product Development, Illumina

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

3月7日（火）

8:00 am Chairperson's Remarks
Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation

8:05 am PANEL DISCUSSION: Big Diagnostics: 30 Years of Impact
Moderator: Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation
Healthcare depends on diagnostics. We all know that diagnostics is the glue that holds the healthcare together and that 70% of medical decisions are informed by a diagnostic - but does that say enough? More than 3.5 million people work in diagnostic industry. The number of companies is at an all-time high. COVID showed the world how valuable a test can be. But with all the changes of the last few years - there have been constants - the industry's largest players. From the labs to manufacturers, from services to products, there are a few companies that have seen it all. In this panel, we talk to them about the good and bad, challenges and opportunities and most importantly, the impact of the last 30 years.

Panelists:

Dave Persing, MD, PhD, Executive Vice President, CSO, Cepheid; CSO, Danaher Diagnostics Platform

Jay Wohlgemuth, MD, CMO and Senior Vice President, R&D, Medical and Population Health, Quest Diagnostics

William G. Morice II, MD, PhD, President & CEO, Mayo Clinic Laboratories; Professor & Past Chair, Mayo Clinic Department of Laboratory Medicine and Pathology; Chair, American Clinical Laboratory Association Board of Directors

Robert Bujarski, President and COO, QuidelOrtho Corporation

4:45 pm Chairperson's Remarks
Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium

4:50 pm Sponsored Presentation (Opportunity Available)

5:00 pm PANEL DISCUSSION: Evaluation and Implementation of Multi-Cancer Early Detection Tests
Moderator: Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium
Multi-cancer early detection promises to improve cancer diagnosis, treatment and patient care. However, introducing MCED technologies into clinical care requires evaluation and assessment of benefits and risks, potential outcomes, costs, and value. The multi-stakeholder expert panel will address how MCED will impact clinical care, outstanding challenges in evidence generation, test reimbursement, market adoption, and equitable patient access.

Panelists:

Philip E. Castle, PhD, MPH, Director, NCI Division of Cancer Prevention, NIH

Tomasz M. Beer, MD, CMO, Multi-Cancer Early Detection, Exact Sciences

3月8日（水）

8:00 am Chairperson's Remarks
Tom Miller, Founder & Managing Partner, GreyBird Ventures, LLC

8:15 am KEYNOTE PRESENTATION: Failure: The Best Way to Learn
Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation
The thought of failure creates fear. The reality of failure creates opportunity. We must embrace failure and all it can teach. As Arianna Huffington said: "Failure is not the opposite of success - it's part of success." We will discuss how to think differently about failing - how to motivate yourself and your teams.

8:30 am PANEL DISCUSSION: Diagnostics Innovation and Investment Trends
Moderator: Tom Miller, Founder & Managing Partner, GreyBird Ventures, LLC
Diagnostics investing experts will review what is hot and what is not in the field. Technological trends and white spaces will be identified, and entrepreneurs will be given best practices to maximize chances for successful financing. The panel will also provide guidance to founders to optimize operational success post-financing and what to do in the event of a stumble, the dreaded pivot, or in dealing with failure.

Panelists:

Ajit Singh, PhD, Partner, Artiman Ventures

Nathan Davis, Analyst, RA Capital Management

John W. Czajka, PhD, MBA, Director, Strategy and Innovation, BD Integrated Diagnostic Solutions

Bruce J. Tromberg, PhD, Director, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health; Lead, NIH's Rapid Acceleration of Diagnostic Technologies (RADx Tech) Program

Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

参加型パスのお申込みは終了致しました。
オンデマンドパスは引き続きお申込み頂けます。
下記ボタンよりご連絡下さい。

Choose your language

カンファレンスプログラム

2023年3月6-7日

2023年3月7-8日